Third Dose of COVID-19 Vaccine Significantly Increases Immune Responses in Most Patients With Multiple Myeloma

Mount Sinai Researchers Receive $7 Million to Improve Outcomes for High-risk Blood Cancer Patients From the Multiple Myeloma Research Foundation

Diabetes May Accelerate Blood Cancer Growth, Yet Survival Outcomes Differ by Race

Researchers Find Treatment Options for Patients Whose Blood Cancer Relapses After CAR-T

Third dose of COVID-19 vaccine significantly increases immune responses in most patients with multiple myeloma

Third Dose of COVID-19 Vaccine Significantly Increases Immune Responses in Most Patients With Multiple Myeloma

Potentially Serious Side Effect Seen in Patient after Immunotherapy

Cancer Patients With Poor Antibody Response to COVID-19 Vaccines Also Lack Secondary Immune Response, Study Shows

Response to COVID-19 Vaccines Varies Widely in Blood Cancer Patients

"Mount Sinai Researchers Use Multi-Omics Approach To Personalize Relapsed Multiple Myeloma Treatment" - John Gilmore